Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G CYBIN INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Yorkville International Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G SCYNEXIS INC Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Churchill Capital Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G XPLR Infrastructure, LP Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G RRE Ventures Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Churchill Capital Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G West Enclave Merger Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G RMG ML Sports Holdings Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G CH4 Natural Solutions Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Viking Acquisition Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G NextCure, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Centessa Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Texas Ventures Acquisiti Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G NewHold Investment Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A MONRO, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Patriot Acquisition Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A BRIGHT MINDS BIOSCIENCES Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Oceanhawk Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Bleichroeder Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Long Table Growth Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G KPET Ultra Paceline Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Irenic Acquisition Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Iron Dome Acquisition I Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Aura Biosciences, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Inflection Point Acquisi Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G AmperCap Acquisition Co Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Gores Holdings XI, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G EyePoint, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G ACP Holdings Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G General Catalyst Global Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Snow Rothschild Acquisit Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Forte Biosciences, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.
-
Ensysce Biosciences acquires Cy Biopharma with up to $77M financing
-
Camp4 Therapeutics closes second tranche of $100M private placement
-
LB Pharmaceuticals raises $150 million in private placement
-
Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial
-
Research Alliance Corporation IV prices $75M IPO on Nasdaq
-
Form SCHEDULE 13G Nine Energy Service, Filed by: Adage Capital Management, L.P.
-
Form 13F-NT Adage Capital Management For: Mar 31
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Mar 31
-
Form SCHEDULE 13G X3 Acquisition Corp. Filed by: Adage Capital Management, L.P.
